Oligoclonal bands are present in the cerebrospinal fluid of most patients with multiple sclerosis (MS) and represent a useful diagnostic measure. Two recent studies indicate that the identification of such bands might provide insight into the underlying mechanism of disease in MS and guide the treatment of individuals with this disorder.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Advanced MRI features in relapsing multiple sclerosis patients with and without CSF oligoclonal IgG bands
Scientific Reports Open Access 13 August 2020
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Lundkvist, M., Greiner, E., Hillert, J. & Fogdell-Hahn, A. Multiple sclerosis patients lacking oligoclonal bands in the cerebrospinal fluid are less likely to develop neutralizing antibodies against interferon beta. Mult. Scler. 16, 796–800 (2010).
Bosca, I. et al. Response to interferon in multiple sclerosis is related to lipid-specific oligoclonal IgM bands. Mult. Scler. 16, 810–815 (2010).
Garcia-Barragan, N. et al. Multiple sclerosis patients with anti-lipid oligoclonal IgM show early favourable response to immunomodulatory treatment. Eur. J. Neurol. 16, 380–385 (2009).
Owens, G. P. et al. Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid. Ann. Neurol. 65, 639–649 (2009).
Avasarala, J. R., Cross, A. H. & Trotter, J. L. Oligoclonal band number as a marker for prognosis in multiple sclerosis. Arch. Neurol. 58, 2044–2045 (2001).
Joseph, F. G. et al. CSF oligoclonal band status informs prognosis in multiple sclerosis: a case control study of 100 patients. J. Neurol. Neurosurg. Psychiatry 80, 292–296 (2009).
Hauser, S. L. et al. B-cell depletion with rituximab in relapsing–remitting multiple sclerosis. N. Engl. J. Med. 358, 676–688 (2008).
Piccio, L. et al. Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. Arch. Neurol. 67, 707–714 (2010).
Bar-Or, A. et al. Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? Ann. Neurol. 67, 452–461 (2010).
Paz Soldan, M. M. et al. Remyelination-promoting antibodies activate distinct Ca2+ influx pathways in astrocytes and oligodendrocytes: relationship to the mechanism of myelin repair. Mol. Cell. Neurosci. 22, 14–24 (2003).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
A. H. Cross has acted as a consultant for and on the speakers' bureau of Bayer Healthcare, Pfizer and Biogen Idec. She has also acted as a consultant for Hoffman-La Roche. G. F. Wu declares no competing interests.
Rights and permissions
About this article
Cite this article
Cross, A., Wu, G. Oligoclonal bands still yield clues about multiple sclerosis. Nat Rev Neurol 6, 588–589 (2010). https://doi.org/10.1038/nrneurol.2010.142
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2010.142
This article is cited by
-
Advanced MRI features in relapsing multiple sclerosis patients with and without CSF oligoclonal IgG bands
Scientific Reports (2020)
-
Distinguishing Susac’s syndrome from multiple sclerosis
Journal of Neurology (2015)
-
Characteristics of Susac syndrome: a review of all reported cases
Nature Reviews Neurology (2013)